Servier agreed to acquire Edgewise Therapeutics’ muscular dystrophy program for $1.55 billion upfront, with total deal value potentially rising to $2.65 billion including milestones. The centerpiece asset is sevasemten, an oral therapy being evaluated in pivotal Becker muscular dystrophy and in a Phase 2 Duchenne muscular dystrophy study. The transaction gives Servier control of a neuromuscular medicine positioned to generate pivotal data within the year, strengthening its neurology pipeline and rare-disease footprint. For Edgewise, the move marks a shift from independent development to a larger company’s late-stage path, while also reflecting ongoing consolidation in muscular dystrophy drug development.